Announced Date: 2025-10-16 (October 16, 2025)
Licensor (Seller): HaiHe Biopharma (China)
Licensee (Buyer): Taiho Pharmaceutical (JP)
.
Asset Name: Risovalisib (CYH33)
Asset Modality: Small Molecule
Asset Target: PI3Kα inhibitor
Potential Indication: ovarian clear cell carcinoma (OCCC)
Current Stage: NDA in Japan, in August 2025
.
Scope of Authority:
Taiho will obtain exclusive rights in Japan to develop, manufacture and commercialize risovalisib.
.
Payment Detail:
Undisclosed.
Haihe will receive an upfront payment, development and sales milestone payments, and royalties based on sales revenue from Taiho.
.
Link:
.
Note:
Chinese Name of Haihe Biopharma 海和药物
